Medicure = World’s Best Telehealth Company

Medicure (TSXV: MPH) is the world’s #1 best telehealth play and sells thousands of drugs online directly to your doorstep at low prices through Marley Drug (click here to see), which partners with drug manufacturers to bypass cost-driving intermediaries and pass the savings directly to its customers.

Medicure is generating huge revenue today through telehealth, allowing it to self-fund the Phase 3 trial of MC-1, which will take only twelve months to complete, and after approval the company will receive a Priority Review Voucher that it will sell for well over US$200 million and return the money to shareholders.

MC-1 is pyridoxal-5′-phosphate (PLP), the active coenzyme form of vitamin B6. We already know that vitamin B6 works for the treatment of PNPO deficiency (click here to see)!

There is currently no FDA-approved treatment for PNPO deficiency, which is why the FDA has granted Medicure (TSXV: MPH) Orphan Drug designation and Fast Track designation for its Phase 3 trial taking place right now.

All other biotech companies with active Phase 3 trials are trading at market caps of at least 5-10x higher than Medicure and don’t have telehealth platforms!

Biotech investors don’t invest in natural resource stocks and have no idea that the TSX Venture exists, so Medicure is overlooked at the moment, but it won’t remain this way for long! It will break out deep into double digits before year-end as word starts to spread!

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.